source
- Novo Nordisk's late-stage anti-inflammatory heart drug fails Phase 3 trialNovo Nordisk announced that its experimental anti-inflammatory compound designed to target cardiovascular inflammation did not meet its primary endpoint in a Phase 3 trial. The study was intended…
- Ratio Therapeutics secures $70M Series C for radiopharma trials as Vogenx eyes $67M IPORatio Therapeutics, a Boston-based biotech, announced a $70 million Series C financing to fund its radiopharmaceutical development program. The round was led by existing backers Duquesne Family Of…